GLAUKOS: Pay

GLAUKOS paid its 4 named executives $26.2M in total in FY2025 (Dec). CEO Thomas W. Burns was paid $12.0M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Thomas W. BurnsChairman and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Joseph E. GilliamPresident and Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Tomas NavratilSenior Vice President and Chief Development Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Alex R. ThurmanSenior Vice President and Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $13.4M. The CEO of GLAUKOS was paid $12.0M, 10% below the median.

  1. 1Natera
  2. 2INSMED
  3. 3Ionis Pharmaceuticals
  4. 4GLAUKOS
  5. 5TransMedics Group
  6. 6Repligen
  7. 7Apellis PharmaceuticalsNot disclosed
  8. 8AxonicsNot disclosed
  9. 9Blueprint MedicinesNot disclosed
  10. 10BridgeBio PharmaceuticalsNot disclosed
  11. 11CONMEDNot disclosed
  12. 12Exact SciencesNot disclosed
  13. 13HaemoneticsNot disclosed
  14. 14HalozymeNot disclosed
  15. 15Inari MedicalNot disclosed
  16. 16Inspire MedicalNot disclosed
  17. 17Intra-CellularNot disclosed
  18. 18Lantheus HoldingsNot disclosed
  19. 19STAAR SurgicalNot disclosed
  20. 20Ultragenyx PharmaceuticalsNot disclosed
  21. 21VericelNot disclosed
  22. 22iRhythm TechnologiesNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.